Belgium-biotech Imcyse is developing IMCY-0098, spinoff intellectual property developed at KU Leuven. A recent Phase I trial enrolled 41 patients newly diagnosed with type 1 diabetes. The investigational drug not only met its endpoint safely but also revealed...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
